Gregorio Rosenstein, MD
Internal Medicine · Chicago, ILNPI 1619936093
Payments from drug & device makers
Across 153 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$446
- AstraZeneca$338
- Pfizer$301
- AbbVie$268
- Lilly USA, LLC$215
- Novo Nordisk$205
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,855100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 27 | $446 |
| AstraZeneca | 15 | $338 |
| Pfizer | 11 | $301 |
| AbbVie(2 entities) | 15 | $268 |
| Lilly USA, LLC | 12 | $215 |
| Novo Nordisk | 16 | $205 |
| Novartis | 11 | $203 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| Bayer | 5 | $135 |
| Almatica Pharma LLC | 9 | $135 |
| Exact Sciences | 5 | $108 |
| Amgen | 3 | $49 |
| Abbott | 2 | $41 |
| Sanofi-aventis U.S. LLC | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Tactile Systems Technology Inc | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Mylan Specialty L.p. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
How this compares
$2,855 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 300 | $114,317 |
| JardianceEmpagliflozin | 83 | $84,974 |
| OzempicSemaglutide | 40 | $65,117 |
| Dupixent SyringeDupilumab | 12 | $45,097 |
| JanuviaSitagliptin Phosphate | 40 | $40,204 |
| MounjaroTirzepatide | 34 | $40,152 |
| FarxigaDapagliflozin Propanediol | 30 | $28,655 |
| XareltoRivaroxaban | 35 | $27,752 |
| EntrestoSacubitril/Valsartan | 46 | $25,678 |
| TrulicityDulaglutide | 23 | $24,824 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $24,260 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $18,996 |
| LinzessLinaclotide | 23 | $18,848 |
| TradjentaLinagliptin | 44 | $17,537 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $12,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $301 | $114,317300 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $23 | $109,358140 claims |
| Novo NordiskOzempic | $205 | $65,11740 claims |
| Lilly USA, LLCMounjaro, Trulicity | $215 | $64,97657 claims |
| MerckJanuvia | $30 | $40,20440 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $446 | $31,90252 claims |
| AstraZenecaFarxiga | $338 | $28,65530 claims |
| NovartisEntresto | $203 | $25,67846 claims |
| AbbVieLinzess | $268 | $18,84823 claims |
| Sanofi-aventis U.S. LLCLantus | $39 | $2,55415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.